CL2016002562A1 - Régimen de dosificación de liberación inmediata de moduladores s1p. - Google Patents
Régimen de dosificación de liberación inmediata de moduladores s1p.Info
- Publication number
- CL2016002562A1 CL2016002562A1 CL2016002562A CL2016002562A CL2016002562A1 CL 2016002562 A1 CL2016002562 A1 CL 2016002562A1 CL 2016002562 A CL2016002562 A CL 2016002562A CL 2016002562 A CL2016002562 A CL 2016002562A CL 2016002562 A1 CL2016002562 A1 CL 2016002562A1
- Authority
- CL
- Chile
- Prior art keywords
- modulators
- immediate release
- dosing regime
- regime
- dosing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461977816P | 2014-04-10 | 2014-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016002562A1 true CL2016002562A1 (es) | 2017-07-28 |
Family
ID=52988364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016002562A CL2016002562A1 (es) | 2014-04-10 | 2016-10-07 | Régimen de dosificación de liberación inmediata de moduladores s1p. |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20170027907A1 (enExample) |
| EP (3) | EP4074312A1 (enExample) |
| JP (1) | JP6674903B2 (enExample) |
| KR (2) | KR20220156981A (enExample) |
| CN (2) | CN116650467A (enExample) |
| AU (2) | AU2015246036A1 (enExample) |
| CA (1) | CA2943598C (enExample) |
| CL (1) | CL2016002562A1 (enExample) |
| IL (2) | IL305337A (enExample) |
| MX (1) | MX2016013245A (enExample) |
| PH (1) | PH12016501965A1 (enExample) |
| RU (2) | RU2020107732A (enExample) |
| SG (1) | SG11201607894RA (enExample) |
| TW (1) | TW201622721A (enExample) |
| WO (1) | WO2015155709A1 (enExample) |
| ZA (1) | ZA201606519B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| MX2016013245A (es) * | 2014-04-10 | 2017-01-16 | Novartis Ag | Regimen de dosificacion de liberacion inmediata de moduladores s1p. |
| US11629124B2 (en) | 2017-03-09 | 2023-04-18 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
| US11434200B2 (en) | 2017-03-09 | 2022-09-06 | Novartis Ag | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof |
| US20200316021A1 (en) * | 2017-09-29 | 2020-10-08 | Novartis Ag | Dosing Regimen of Siponimod |
| CN111132677A (zh) * | 2017-09-29 | 2020-05-08 | 诺华股份有限公司 | 西尼莫德的给药方案 |
| HRP20250115T1 (hr) * | 2018-03-01 | 2025-05-23 | Astrazeneca Ab | Farmaceutski pripravci koji sadrže (2s)-{(1s)-1-cijano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil} -1,4-oksazepan-2-karboksamid |
| CA3106269A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
| CN109908095A (zh) * | 2019-04-08 | 2019-06-21 | 肇庆学院 | 一种西尼莫德片剂及制备方法 |
| PH12022551043A1 (en) | 2019-10-31 | 2023-05-03 | Idorsia Pharmaceuticals Ltd | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
| WO2021158838A1 (en) * | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Dosage regimen of an s1p receptor modulator |
| AU2024206233A1 (en) | 2023-01-06 | 2025-08-21 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG171785A1 (en) * | 2008-12-18 | 2011-07-28 | Novartis Ag | Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid |
| MX367667B (es) | 2008-12-22 | 2019-08-30 | Novartis Ag | Régimen de dosificación de un agonista de los receptores de s1p. |
| DK2379067T3 (en) * | 2008-12-22 | 2015-12-07 | Novartis Ag | Dosing regimen to fingolimod FOR THE TREATMENT OF MULTIPLE SCLEROSIS |
| CA2773330C (en) * | 2009-09-29 | 2021-11-02 | Novartis Ag | Dosage regimen of an s1p receptor modulator |
| BR112013017302B1 (pt) * | 2011-01-07 | 2021-12-07 | Novartis Ag | Composição farmacêutica em fase sólida |
| WO2012095853A1 (en) | 2011-01-10 | 2012-07-19 | Novartis Pharma Ag | Modified release formulations comprising sip receptor modulators |
| KR20140084041A (ko) * | 2011-10-21 | 2014-07-04 | 노파르티스 아게 | S1p 수용체 조절제 또는 효능제에 대한 투여 요법 |
| MX2016013245A (es) * | 2014-04-10 | 2017-01-16 | Novartis Ag | Regimen de dosificacion de liberacion inmediata de moduladores s1p. |
-
2015
- 2015-04-08 MX MX2016013245A patent/MX2016013245A/es unknown
- 2015-04-08 TW TW104111330A patent/TW201622721A/zh unknown
- 2015-04-08 CN CN202310667400.7A patent/CN116650467A/zh active Pending
- 2015-04-08 CN CN201580031360.0A patent/CN106456552A/zh active Pending
- 2015-04-08 CA CA2943598A patent/CA2943598C/en active Active
- 2015-04-08 RU RU2020107732A patent/RU2020107732A/ru unknown
- 2015-04-08 EP EP21212400.2A patent/EP4074312A1/en active Pending
- 2015-04-08 SG SG11201607894RA patent/SG11201607894RA/en unknown
- 2015-04-08 US US15/300,989 patent/US20170027907A1/en not_active Abandoned
- 2015-04-08 EP EP20215763.2A patent/EP3831378A1/en not_active Withdrawn
- 2015-04-08 JP JP2016561731A patent/JP6674903B2/ja active Active
- 2015-04-08 KR KR1020227039781A patent/KR20220156981A/ko not_active Ceased
- 2015-04-08 RU RU2016143979A patent/RU2715734C2/ru not_active Application Discontinuation
- 2015-04-08 EP EP15717256.0A patent/EP3129020A1/en not_active Withdrawn
- 2015-04-08 AU AU2015246036A patent/AU2015246036A1/en not_active Abandoned
- 2015-04-08 WO PCT/IB2015/052550 patent/WO2015155709A1/en not_active Ceased
- 2015-04-08 KR KR1020167031062A patent/KR20160141841A/ko not_active Ceased
- 2015-04-08 IL IL305337A patent/IL305337A/en unknown
-
2016
- 2016-09-21 ZA ZA2016/06519A patent/ZA201606519B/en unknown
- 2016-09-22 IL IL247986A patent/IL247986A0/en unknown
- 2016-10-04 PH PH12016501965A patent/PH12016501965A1/en unknown
- 2016-10-07 CL CL2016002562A patent/CL2016002562A1/es unknown
-
2018
- 2018-08-21 US US16/106,072 patent/US20190054065A1/en not_active Abandoned
-
2020
- 2020-05-12 AU AU2020203107A patent/AU2020203107B2/en active Active
- 2020-06-02 US US16/890,722 patent/US20220016076A1/en not_active Abandoned
-
2024
- 2024-10-23 US US18/924,230 patent/US20250041266A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4074312A1 (en) | 2022-10-19 |
| CA2943598C (en) | 2023-03-07 |
| US20220016076A1 (en) | 2022-01-20 |
| SG11201607894RA (en) | 2016-10-28 |
| JP6674903B2 (ja) | 2020-04-01 |
| MX2016013245A (es) | 2017-01-16 |
| RU2016143979A (ru) | 2018-05-14 |
| US20190054065A1 (en) | 2019-02-21 |
| US20250041266A1 (en) | 2025-02-06 |
| ZA201606519B (en) | 2017-11-29 |
| JP2017510607A (ja) | 2017-04-13 |
| RU2715734C2 (ru) | 2020-03-03 |
| RU2016143979A3 (enExample) | 2018-11-12 |
| EP3831378A1 (en) | 2021-06-09 |
| AU2020203107B2 (en) | 2021-10-21 |
| IL247986A0 (en) | 2016-11-30 |
| CA2943598A1 (en) | 2015-10-15 |
| AU2015246036A1 (en) | 2016-10-13 |
| CN106456552A (zh) | 2017-02-22 |
| KR20160141841A (ko) | 2016-12-09 |
| CN116650467A (zh) | 2023-08-29 |
| PH12016501965A1 (en) | 2017-01-09 |
| EP3129020A1 (en) | 2017-02-15 |
| KR20220156981A (ko) | 2022-11-28 |
| US20170027907A1 (en) | 2017-02-02 |
| AU2020203107A1 (en) | 2020-05-28 |
| IL305337A (en) | 2023-10-01 |
| TW201622721A (zh) | 2016-07-01 |
| RU2020107732A (ru) | 2020-03-30 |
| WO2015155709A1 (en) | 2015-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002562A1 (es) | Régimen de dosificación de liberación inmediata de moduladores s1p. | |
| MA43382A (fr) | Modulateurs des récepteurs des chimiokines | |
| DK3331876T3 (da) | Modulators of ror-gamma | |
| HUE061287T2 (hu) | Újratöltõ csomag e-cigarettához | |
| MA53943A (fr) | Modulateurs de ror-gamma | |
| EP3888782C0 (en) | COATED MICROCAPSULES | |
| DK3236943T3 (da) | Sammensætninger til ileo-jejunal lægemiddeladministration | |
| DK3131902T3 (da) | Forbindelser som ROR-gamma-modulatorer | |
| PT3177329T (pt) | Sistema para a libertação imediata de agentes ativos | |
| DK3229810T3 (da) | Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler | |
| EP3868427C0 (en) | SAFETY SYRINGE SYSTEM | |
| HUE043290T2 (hu) | Adagoló kapszula | |
| DK3125898T3 (da) | Farmakofor til trail-induktion | |
| ES1137034Y (es) | Cápsula para sólidos | |
| DK3145488T3 (da) | Flydende farmaceutiske forbindelse | |
| BR112016020077A2 (pt) | composições de lactase líquida | |
| DK3230929T3 (da) | Forbedringer til tælleranordninger | |
| DK3153508T3 (da) | Naphthofuranderivater til anvendelse som anticancermidler | |
| MA41266A (fr) | Cataplasme | |
| DK3145916T3 (da) | Imidazolderivater som formylpeptidreceptormodulatorer | |
| DK2946774T3 (da) | Coatede kapsler med modificeret frigivelse | |
| FR3030466B3 (fr) | Valve doseuse multilame | |
| DE112015005590A5 (de) | Dosierpumpe | |
| EP3181125C0 (en) | CAPSULE FORMULATION | |
| DK3089740T3 (da) | Farmaceutisk sammensætning |